Entering text into the input field will update the search result below

Acer Therapeutics GAAP EPS of -$0.31 misses by $0.30, revenue of $0.36M misses by $2.97M

Mar. 02, 2022 5:26 PM ETAcer Therapeutics Inc. (ACER) StockBy: Pranav Ghumatkar, SA News Editor
  • Acer Therapeutics press release (NASDAQ:ACER): Q4 GAAP EPS of -$0.31 misses by $0.30.
  • Revenue of $0.36M misses by $2.97M.
  • Ended Q4 2021 with $12.7 million in cash and cash equivalents. Acer believes its cash and cash equivalents available as of December 31, 2021.

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About ACER

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Acer Therapeutics Inc.
Aytu BioPharma, Inc.
Spyre Therapeutics, Inc.
Astellas Pharma Inc.
AstraZeneca PLC
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.